Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • No cookie-cutter divorces, so what info should online co-parenting classes offer?

  • Healthy working environment is a salvation

  • Warm thanks: Gratitude can win you new friends

  • Learning to read: Tricking the brain

  • Meaningful relationships can help you thrive

  • Memory in silent neurons: How do unconnected neurons communicate?

  • Brain networks 'hyper-connected' in young adults who had depression

  • New treatment for Multiple Sclerosis being investigated

  • How does it feel to be old in different societies?

  • Bedsharing with baby may impair sleep quality

  •